Back to Search Start Over

Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation.

Authors :
Iftikhar R
Chaudhry QUN
Satti TM
Mahmood SK
Ghafoor T
Shamshad GU
Shahbaz N
Khan MA
Khattak TA
Rehman J
Farhan M
Humayun S
Haq H
Naqvi SAA
Anwer F
Satti HS
Ahmed P
Source :
Clinical hematology international [Clin Hematol Int] 2020 May 18; Vol. 2 (2), pp. 82-91. Date of Electronic Publication: 2020 May 18 (Print Publication: 2020).
Publication Year :
2020

Abstract

Allogeneic stem cell transplant for high-risk aplastic anemia (AA) yields inferior results using conventional cyclophosphamide (CY)-based conditioning. The use of fludarabine (Flu)-based regimens has resulted in improved outcomes in high-risk patients. Limited data are available comparing these two conditioning regimens in such patients. We retrospectively analyzed 192 high-risk patients undergoing matched-related donor transplantation from July 2001 to December 2018. The median age was 19.5 (2-52) years. Patients were divided into 2 groups, Cy <superscript>200</superscript> anti-thymocyte globulin (ATG) <superscript>20</superscript> (Gp1 n = 79) or Flu <superscript>120-150</superscript> Cy <superscript>120-160</superscript> ATG <superscript>20</superscript> (Gp2 n = 113). The risk of graft failure was significantly higher in Gp1, and the majority occurred in patients with >2 risk factors ( p = 0.02). The incidence of grade II-IV acute graft versus host disease (GVHD) and chronic GVHD was not significantly different between the two groups. The overall survival (OS) of the study cohort was 81.3 %, disease-free survival (DFS) 76.6 % and GVHD-free relapse-free survival (GRFS) was 64.1%. DFS and GRFS were significantly higher in Gp2 as compared to Gp1: DFS 84.1% versus 68.4 % ( p = 0.02), GRFS 77.9% versus 54.4% ( p = 0.01), respectively. We conclude that Flu-based conditioning is associated with superior OS, DFS and GRFS as compared to the conventional Cy-based regimen in high-risk AA.<br />Competing Interests: This manuscript contains original research not previously published or submitted for publication elsewhere while under consideration. The authors declare no conflict of interest with this manuscript.<br /> (© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.)

Details

Language :
English
ISSN :
2590-0048
Volume :
2
Issue :
2
Database :
MEDLINE
Journal :
Clinical hematology international
Publication Type :
Academic Journal
Accession number :
34595447
Full Text :
https://doi.org/10.2991/chi.d.200426.001